Research into myelofibrosis
Myelofibrosis is a rare blood cancer. It causes scarring of the bone marrow which makes it more difficult to produce blood cells.
Researchers around the world are looking at better ways to treat myelofibrosis and manage treatment side effects. Go to Cancer Research UK’s clinical trials database if you are looking for a trial for myelofibrosis in the UK. You need to talk to your specialist if there are any trials that you think you might be able to take part in.
Some of the trials on this page have now stopped recruiting people. It takes time before the results are available. This is because the trial team follow the patients for a period of time and collect and analyse the results. We have included this ongoing research to give examples of the type of research being carried out in myelofibrosis.
Research and clinical trials
All cancer treatments must be fully researched before they can be used for everyone. This is so we can be sure that:
-
they work
-
they work better than the treatments already available
-
they are safe
To make sure the research is accurate, each trial has certain entry conditions for who can take part. These are different for each trial.
Hospitals do not take part in every clinical trial. Some trials are only done in a small number of hospitals, or in one area of the country. You may need to travel quite far if you take part in these trials.
Myeloproliferative neoplasms
Myelofibrosis is one of a group of conditions called myeloproliferative neoplasms (MPN). They also include:
- essential thrombocythaemia
- polycythaemia vera
JAK2 gene
Researchers are looking at ways to improve the diagnosis and treatment of all MPNs.
Some of this research is suggesting that it may be better to group these cancers depending on whether they are:
- JAK2 positive or
- JAK2 negative
The JAK2 gene makes a protein that controls how many blood cells the stem cells make. A fault with your JAK2 gene means the stem cells can start producing blood cells when they're not meant to. Scientists hope that improving the diagnosis this way might help doctors choose targeted treatments in the future.
How do myeloproliferative neoplasms develop?
Researchers are looking to try to explain how myeloproliferative neoplasms develop. And to use this information to develop new treatments in the future.
Scientists think that MPNs might happen because proteins called tyrosine kinases act as 
and tell cells to keep on dividing. Researchers are looking at white blood cells in samples from people taking part in a study. They are looking for tyrosine kinases and for any features or damage which may make them keep on dividing.
Research into symptoms of myelofibrosis
People with myelofibrosis can have a range of symptoms. These symptoms can affect different parts of their body. Researchers are looking at ways to collect information about the symptoms people have.
Research into treatment for myelofibrosis
Ruxolitinib
Ruxolitinib is a cancer . It is already used to treat the symptoms of myelofibrosis. It's called a JAK2 inhibitor.
Researchers want to know if this drug can be used in other ways to treat myelofibrosis.
Trial teams are also looking at whether ruxolitinib can be combined with other drugs to improve treatment. These other drugs include:
-
azacitidine - a chemotherapy drug
-
PLX 2853 a targeted drug
-
navitoclax
-
INCB057643 - a targeted drug
Other drugs
Scientists are looking at a targeted cancer drug called KRT-232. The study team are trying to find out if this drug helps people when JAK inhibitors, such as ruxolitinib, are no longer helping.
Researchers are also looking at:
-
fedratinib
-
momelotinib
-
givinostat
Treatment to prevent GvHD after a stem cell transplant
A team of doctors is comparing with 2 newer combinations of treatment to prevent graft versus host disease (GvHD).
Graft versus host disease (GvHD) is a possible complication of a from another person. GvHD happens when particular types of white blood cells (T cells) in the donated stem cells or bone marrow attack your own body cells. This is because the donated cells (the graft) see your body cells (the host) as foreign and attack them.
We know from research that some newer combinations of treatment may help to reduce the risk of GvHD. But they haven’t been compared to the standard treatments used in the UK. So the team is running this trial to find out more.
Cancer Research UK Clinical Trials Database
You can find a clinical trial looking at myelofibrosis on our clinical trials database. Click on the ‘recruiting’, ‘closed’ and ‘results’ tabs to make sure you see all the trials.
